Platelet-derived growth factor (PDGF) acts through two conserved receptor tyrosine kinases: PDGFRα and PDGFRβ. Gain-of-function mutations in human PDGFRB have been linked recently to genetic diseases characterized by connective tissue wasting (Penttinen syndrome) or overgrowth (Kosaki overgrowth syndrome), but it is unclear whether PDGFRB mutations alone are responsible. Mice with constitutive PDGFRβ signaling caused by a kinase domain mutation [D849V] develop lethal autoinflammation. Here we used a genetic approach to investigate the mechanism of autoinflammation in Pdgfrb<sup>+/D849V</sup> mice and test the hypothesis that signal transducer and activator of transcription 1 (STAT1) mediates this phenotype. We show that Pdgfrb<sup>+/D849V</sup> mice with Stat1 knockout [Stat1<sup>−/−</sup> Pdgfrb<sup>+/D849V</sup>] are rescued from autoinflammation and have improved life span compared with Stat1<sup>+/+</sup> Pdgfrb<sup>+/D849V</sup> mice. Furthermore, PDGFRβ–STAT1 signaling suppresses PDGFRβ itself. Thus, Stat1<sup>−/−</sup> Pdgfrb<sup>+/D849V</sup> fibroblasts exhibit increased PDGFRβ signaling, and mice develop progressive overgrowth, a distinct phenotype from the wasting seen in Stat1<sup>+/−</sup> Pdgfrb<sup>+/D849V</sup> mice. Deletion of interferon receptors (Ifnar1 or Ifngr1) does not rescue wasting in Pdgfrb<sup>+/D849V</sup> mice, indicating that interferons are not required for autoinflammation. These results provide functional evidence that elevated PDGFRβ signaling causes tissue wasting or overgrowth reminiscent of human genetic syndromes and that the STAT1 pathway is a crucial modulator of this phenotypic spectrum.

[Keywords: STAT; interferon; inflammation; skeleton; dermis; adipose tissue; fibrosis]

Supplemental material is available for this article.

Received April 11, 2017; revised version accepted August 21, 2017.

© 2017 He et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date [see http://genesdev.cshlp.org/site/misc/terms.xhtml]. After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
D849V mutation in epiblast-derived cells, Sox2-Cre;Pdgfrb\(^{+/D849V}\) mutants died by 2 wk of age with three principal phenotypes: VSMC hyperplasia and dilation of the aorta, autoinflammation with infiltration of leukocytes into the tissues, and lipoatrophy [Olson and Soriano 2011]. While VSMC defects were not entirely surprising given the known biology of PDGFRβ, the causes of autoinflammation, tissue atrophy, and juvenile lethality remain mysterious.

Recently, PDGFRβ-activating mutations have been linked to rare human syndromes affecting the skin, fat, and bones. Kosaki overgrowth syndrome [Online Mendelian Inheritance in Man [OMIM] 616592] is characterized by increased linear growth during adolescence and has been linked to P584R or W566R mutations in the juxtamembrane domain of PDGFRβ [Takenouchi et al. 2015; Minatogawa et al. 2017]. Penttinen syndrome [OMIM 601812] is a clinically distinct condition characterized by a prematurely aged appearance with dermal wasting, lipoatrophy, and bone loss, which has been linked to V665A mutations in the kinase domain [Johnston et al. 2015]. Other activating mutations have been identified in infantile myofibromatosis, a soft tissue tumor of early childhood [Cheung et al. 2013; Martignetti et al. 2013]. Several of these PDGFRβ mutations have been shown to generate constitutive PDGFRβ signaling [Johnston et al. 2015; Arts et al. 2016], supporting the idea that disease arises by gain-of-function mechanisms. However, there is still no clear evidence that PDGFRβ activation alone can cause connective tissue phenotypes. In many cases of cancer and genetic diseases, additional mutations are required or have the ability to modify disease phenotypes. Moreover, there is currently no model of pathogenesis to explain the spectrum of phenotypes associated with activating mutation in PDGFRβ. This is in contrast to genetic evidence from mice and humans that loss-of-function mutations in PDGFRβ or PDGFB cause idiopathic basal ganglion calcification type 4 [Keller et al. 2013; Nicolas et al. 2013].

The initial goal of this study is to explain the autoinflammation and causes of death in Sox2-Cre Pdgfrb\(^{+/D849V}\) mutant mice. Because microarray analysis demonstrated upregulation of interferon (IFN)-stimulated genes (ISGs) in the tissue of Sox2-Cre Pdgfrb\(^{+/D849V}\) mutants [Olson and Soriano 2011], we hypothesized that gain-of-function PDGFRβ signaling might cause autoinflammation via STAT1. Wild-type PDGFRβ is known to phosphorylate and activate STAT1 [Silvennoinen et al. 1993], a principal signal-transducing transcription factor in the IFN pathway (Levy and Darnell 2002), but the biological significance of PDGFRβ–STAT1 signaling is still unknown. Our hypothesis is supported by recent findings that tissue-specific Stat1 knockout in PDGFRβ\(^{D849V}\)-expressing VSMCs significantly reduced vascular inflammation and atherosclerosis in ApoE-deficient mice [He et al. 2015]. Therefore, we generated mice with germline Stat1 and/or Pdgfrb mutations in epiblast-derived cells using Sox2-Cre. The use of Sox2-Cre approximates a sporadic Pdgfrb mutation in the early embryo that is proposed to occur in the human syndromes. These experiments revealed that PDGFRβ–STAT1 signaling is indeed responsible for autoinflammation, lipoatrophy, and juvenile lethality. We also identified skeletal degeneration as a new phenotype driven by PDGFRβ–STAT1 signaling. In cultured fibroblasts, STAT1 mediates negative feedback to suppress PDGFRβ expression and function. Correspondingly, in the absence of STAT1, PDGFRβ\(^{D849V}\)-expressing mice develop novel phenotypes, including fibrosis of the skin and fat and skeletal overgrowth. Together, these findings provide the first functional evidence that PDGFRβ mutations cause skin and skeleton phenotypes. This provides strong evidence that PDGFRβ mutations identified in Penttinen syndrome and Kosaki overgrowth syndrome are causal. In addition, these results suggest that the STAT1 pathway is a crucial disease modifier in PDGFRβ-related syndromes involving connective tissue degeneration or overgrowth.

Results
Activated STAT1 becomes phosphorylated on Tyr701 [Y701], which allows STAT1 dimers to enter the nucleus and activate ISG expression. We initially examined the effects of different PDGFRβ-activating mutations on STAT1 phosphorylation, since this has not been reported for the mutations linked to human disease. Therefore, we transfected NIH3T3 cells with expression vectors encoding GFP, murine wild-type PDGFRβ, PDGFRβ\(^{D849V}\), PDGFRβ\(^{D849V}\)–Stat1\(^{−/−}\) [corresponding to human P584R, Kosaki overgrowth syndrome], or PDGFRβ\(^{V664A}\) [corresponding to human V665A, Penttinen syndrome]. Under low-serum conditions, STAT1 was highly phosphorylated by all mutants, as compared with GFP or wild-type PDGFRβ [Fig. 1A]. This suggests that constitutive PDGFRβ–STAT1 signaling is a general feature of PDGFRβ-activating mutations. Notably, overexpression of wild-type PDGFRβ resulted in considerable PDGFRβ autophosphorylation compared with control cells with GFP, but only the mutant receptors were able to phosphorylate STAT1 to a significant level.

We previously described PDGFRβ\(^{D849V}\) knock-in mice [Olson and Soriano 2011]. The D849V point mutation is located in the receptor kinase domain, where it destabilizes the autoinhibited conformation of the receptor and thereby increases kinase activity and downstream signaling. Importantly, this allele is Cre-dependent such that PDGFRβ\(^{D849V}\) is expressed under the control of the endogenous Pdgfrb promoter following Cre/lox deletion of a transcriptional stop cassette [Fig. 1B]. When Sox2-Cre is used to activate this allele in the epiblast, the resulting Sox2-Cre Pdgfrb\(^{+/D849V}\) mice express PDGFRβ\(^{D849V}\) in all PDGFRβ\(^{+}\) cells. These mice fail to thrive and survive only 2 wk postnatal.

Stat1 deletion rescues juvenile wasting in Sox2-Cre Pdgfrb\(^{+/D849V}\) mice
To determine whether the cause of death involves STAT1, we established a breeding strategy using Sox2-Cre for germline deletion of Stat1-floxed alleles and/or activation
of PDGFRβ<sup>D849V</sup>. For simplicity, mice with PDGFRβ<sup>D849V</sup> are designated K, for the kinase domain mutation. We thus generated four offspring genotypes: Stat1<sup>+/−</sup> [referred to here as S<sup>+/−</sup>], Stat1<sup>−/−</sup> [S<sup>−/−</sup>], Pdgfrb<sup>+/−</sup> Stat1<sup>−/−</sup> [KS<sup>+/−</sup>], and Pdgfrb<sup>−/−</sup> Stat1<sup>−/−</sup> [KS<sup>−/−</sup>] [Fig. 1C]. Importantly, while Stat1-deficient mice are nonresponsive to IFNs, they do not exhibit obvious growth or survival phenotypes unless challenged [Durbin et al. 1996; Meraz et al. 1996]. Marginally increased bone formation has also been reported in S<sup>+/−</sup> mice compared with S<sup>+/+</sup> mice [Sahni et al. 2001; Kim et al. 2003]. As expected from previous studies, S<sup>+/−</sup> and S<sup>−/−</sup> mice did not have obvious phenotypes. Therefore, we focused subsequent analysis on KS<sup>+/−</sup> and KS<sup>−/−</sup> mice. KS<sup>+/−</sup> mice were underweight after day 7 and died in the third week postnatal, but, interestingly, young KS<sup>−/−</sup> mice were normal in overall appearance [Fig. 1D–F]. Therefore, juvenile lethality depends on Stat1. Importantly, even though KS<sup>−/−</sup> mice appeared normal at 3 wk of age, they succumbed to early death at ~8 wk [Fig. 1F].

**PDGFRβ–STAT1 signaling drives autoinflammation**

STAT1 was constitutively phosphorylated in VSMCs from Pdgfrb<sup>+/−</sup> mice [He et al. 2015]. To determine whether this occurs in other cell types, we used PDGF-treated primary dermal fibroblasts [DFs] from the four genotypes of mice described above. STAT1 was not detected in S<sup>+/−</sup> and KS<sup>+/−</sup> DFs. STAT1 became phosphorylated in S<sup>+/−</sup> DFs only after exposure to PDGF-BB but was constitutively phosphorylated in KS<sup>−/−</sup> DFs [Fig. 2A, lane 9]. Many STAT1 target genes are ISGs, a broad class of IFN-inducible genes that includes chemokines (Ccl2, Cxc19, Cxcl10, and Cxcl11), antigen processing and antigen presentation machinery (Psmb8 and B2m), antiviral response factors [Mx1 and Ifi27], and transcription factors [Irf1 and Stat1 itself]. Unstimulated KS<sup>+/−</sup> DFs overexpressed several ISGs (Cxcl10, Psmb8, Mx1, Irf1, and Ifi27) [Supplemental Fig. S1], but ISG expression in KS<sup>−/−</sup> DFs was comparable with S<sup>+/−</sup> DFs. This demonstrates that PDGFRβ<sup>D849V</sup> activates STAT1 and thereby induces ISG expression in DFs.

We also monitored ISG expression in inguinal white adipose tissue [ingWAT], a subcutaneous fat depot that atrophies in Sox2-Cre Pdgfrb<sup>+/−</sup> [KS<sup>+/−</sup>] mice [Olson and Soriano 2011]. Stat1 was overexpressed in KS<sup>−/−</sup> compared with S<sup>+/−</sup> fat [Fig. 2B]. B2m, Ccl2, Cxc19, Cxcl10, and Cxcl11 were also overexpressed in KS<sup>−/−</sup> fat, but their expression in KS<sup>−/−</sup> was comparable with S<sup>+/−</sup> and S<sup>−/−</sup> fat [Fig. 2B,C]. Next, we used flow cytometry to quantify the infiltration of CD45<sup>+</sup> leukocytes into the tissue. KS<sup>−/−</sup> fat contained more cells overall compared with other genotypes, and a greater percentage of these cells were CD11b<sup>−</sup>, leukocytes. Mirroring ISG expression, full deletion of Stat1 in KS<sup>−/−</sup> mice reduced leukocyte infiltration to the level of S<sup>+/−</sup> and S<sup>−/−</sup> mice [Fig. 2D,E]. Histological changes in the fat pad also tracked ISG expression, as KS<sup>−/−</sup> fat at day 14 had an atrophied appearance with small adipocytes and abundant stromal cells and leukocytes, but KS<sup>−/−</sup> was indistinguishable from S<sup>+/−</sup> or S<sup>−/−</sup> fat [Fig. 2F]. Taken together, these data demonstrate that STAT1 is required for PDGFRβ-driven autoinflammation characterized by ISG up-regulation and leukocyte infiltration into peripheral tissues.
STAT1 suppresses PDGFRβ expression and signaling in DFs

The rescue of lethal wasting by Stat1 knockout prompted us to investigate PDGFRβ expression and downstream signaling in cells from the affected mice. PDGFRβ mRNA and protein levels were significantly reduced in KS+/− DFs compared with S+− and S−/− DFs (Fig. 3A). This is consistent with previous microarray data showing a 50% reduction of Pdgfrb expression in Pdgfrb+/D849V pericytes compared with wild type (GSE29284) (Olson and Soriano 2011). However, complete Stat1 deletion fully restored mRNA levels and partially restored protein levels in KS−/− DFs (Fig. 3A,B). PDGFRβ is constitutively autophosphorylated in PDGFRβD849V-expressing embryonic fibroblasts and adult VSMCs (Olson and Soriano 2011; He et al. 2015). To investigate whether Stat1 deletion has an effect on PDGFRβ autophosphorylation, we serum-starved DFs and examined phosphorylation under basal conditions or after PDGF treatment. As expected, PDGFRβ phosphorylation was low in S−/− and S+− DFs under serum-starved conditions. Basal phosphorylation was increased in KS+− and KS−/− DFs compared with S+− and S−/− DFs but was significantly stronger in KS−/− compared with KS+− (P < 0.01) (Fig. 3C). PDGF induced strong PDGFRβ phosphorylation in all genotypes, with a trend toward the highest response in KS−/− cells. These data indicate that STAT1 negatively regulates Pdgfrb gene expression and signaling.

We showed previously that PLCγ was constitutively phosphorylated in KS−/− mouse embryonic fibroblasts, while two other PDGF pathway effectors, Akt and Erk1/2, were phosphorylated only in response to PDGF (Olson and Soriano 2011). We asked whether Stat1 deletion alters these events. Once again, the phosphorylation of Akt and Erk1/2 was PDGF-dependent in all DF genotypes (Supplemental Fig. S2). Also, as shown previously, PLCγ was constitutively phosphorylated in KS−/− DFs compared with S−/− DFs (Fig. 3D, lane 5 vs. lane 1), but PDGF-induced phosphorylation was blunted in KS−/− compared with other genotypes (Fig. 3D, lane 6 vs. lane 2). Furthermore, Stat1 deletion resulted in stronger basal PLCγ phosphorylation in KS−/− DFs compared with S−/− DFs (Fig. 3D, lane 7 vs. lane 5). We also examined STAT3 and STAT5, two other PDGF-regulated STATs, and found them constitutively phosphorylated in serum-starved KS+− and KS−/− DFs compared with S+− and S−/− (Fig. 3E,F). Therefore, PLCγ phosphorylation by PDGFRβD849V is enhanced by Stat1 deletion, but there is no effect on constitutive STAT3/5 phosphorylation.

Taken together, these results demonstrate that STAT1 suppresses the gain-of-function signaling exerted by
PDGFRβ<sup>D849V</sup> The mechanism of suppression might involve STAT1-dependent ISGs that exert negative feedback on upstream signaling. For example, the suppressor of cytokine signaling (SOCS) family of proteins consists of negative regulators of cytokine and some growth factor signaling cascades [Linossi et al. 2013; Kazi et al. 2014]. We analyzed the expression of eight SOCS members (SOCS1−7 and CIS) in cultured DFs. Socs4−7 expression did not differ greatly between genotypes. However, Socs1 and Socs3 exhibited a trend of up-regulation only in KS<sup>−/−</sup> DFs, suggestive of regulation like other ISGs [Supplemental Fig. S3]. Therefore, if any SOCS proteins mediate negative feedback on PDGFRβ, SOCS1 and SOCS3 would be the best candidates. In contrast, Socs2 and Cis were up-regulated in KS<sup>−/−</sup> DFs [approximately threefold] and further overexpressed in KS<sup>−/−</sup> DFs (~40-fold and ~10-fold, respectively) [Supplemental Fig. S3]. This suggests changes in STAT-regulated transcription, where STAT1 opposes the function of other pathways/effectors that stimulate Socs2 and Cis expression (potentially STAT3/5). The SOCS proteins exert negative feedback on cytokine receptors by inhibiting kinase activity or mediating receptor degradation. However, further studies are needed to determine whether and under what conditions PDGFRβ may be a target of SOCS negative feedback.

STAT1 controls skin and adipose tissue phenotypes linked to PDGFRβ gain of function

Increased PDGFRβ signaling in KS<sup>−/−</sup> DFs suggested that KS<sup>−/−</sup> mice might develop novel phenotypes related to increased signaling in the absence of STAT1. For instance, PDGFR signaling stimulates fibroblast proliferation and extracellular matrix secretion, which can lead to organ fibrosis [Bonner 2004; Andrae et al. 2008]. To identify new phenotypes in KS<sup>−/−</sup> or KS<sup>−/+</sup> littermates were indistinguishable. At 3 wk of age, KS<sup>−/−</sup> skin was very thin without obvious fat, but KS<sup>−/+</sup> skin exhibited an opposite phenotype with a thickened upper dermis [Fig. 4A, double arrow]. Furthermore, the KS<sup>−/−</sup> dWAT exhibited areas of interstitial collagen accumulation and expansion of stromal cells between adipocytes [Fig. 4A, circle]. To quantify fibrosis, we measured the upper dermal thickness from the epidermal–dermal junction to the dermal–fat junction. By this measure, the KS<sup>−/+</sup> dermis was significantly thinner than that of S<sup>−/+</sup>, and there was significant dermal thickening in 3-wk-old KS<sup>−/−</sup> mice [Fig. 4B]. Moreover, by 8 wk of age, the KS<sup>−/−</sup> upper dermis had thickened

![Figure 3. STAT1 suppresses PDGFRβ expression and signaling in DFs.](image-url)
so much that it replaced dWAT, demonstrating the progressive nature of the fibrosis [Supplemental Fig. S5A].

We stained 3-wk-old skin for collagen 3 (Col3) to mark areas of fibrosis or for perilipin (Plin1) to mark adipocytes. Consistent with histological analysis, abundant Col3 protein was detected in the KS+/- dermal fat, particularly in the expanded interstitial space between individual adipocytes [Fig. 4C, circle]. Col3 staining in the S+/+ and S−/− fat was markedly lower than KS+/-/. There was high Col3 staining throughout the KS+/- dermis, probably due in part to compression of the atrophic tissue. Plin1 stains the cytoplasm around the central lipid droplet of each adipocyte, which highlights a ring-like morphology for each adipocyte in S+/+, S−/−, and KS−/− skin. The atrophied KS+/- skin contained very small Plin1+ cells with a fibroblast-like morphology and no obvious lipid droplet [Fig. 4D]. Interestingly, highly fibrotic skin of 8-wk-old KS−/− mice also contained very small Plin1+ cells still embedded in the lower dermis [Supplemental Fig. S5A]. Therefore, in both atrophied KS+/- skin and fibrotic KS−/− skin, Plin1+ adipocytes persist without obvious lipid droplets. Since STAT1 suppressed PDGFRβ expression and signaling [Fig. 3], we examined PDGFRβ expression in skin. In all genotypes, PDGFRβ was highly expressed in the hair follicle dermal sheath and in mural cells surrounding blood vessels. However, exclusively in KS−/− skin, there was strong PDGFRβ expression in the fibroblast-like interstitial cells located in dermal fat [Fig. 4E, circle].

Next, we examined other fat depots, which generally exist in the form of white fat specialized for lipid storage or brown adipose tissue (BAT) specialized for thermogenesis. Like the skin, all tissues from S+/+ and S−/− mice had similar morphology. The remnant of KS+/- ingWAT from 3-wk-old mice contained only stromal vascular cells without obvious adipocytes [Fig. 5A]. The KS+/- ingWAT at 3 wk appeared grossly normal, but some perivascular fibrosis was apparent by trichrome stain (Fig. 5A arrows). By 8 wk, KS−/− ingWAT was highly fibrotic [Fig. 5B]. Like the skin, Plin1+ fibroblast-like cells were still detectable in the atrophied remnant of KS−/− ingWAT at 3 wk [Supplemental Fig. S5B] and also in the fibrotic remnant of KS+/- ingWAT at 8 wk [Supplemental Fig. S5C]. Perigonal dWAT (pWAT) displayed a similar trend of rapid atrophy in KS+/- mice and slower fibrotic remodeling in KS−/− mice [Fig. 5C,D]. In contrast, BAT was resistant to atrophy in KS+/- mice, and minimal perivascular fibrosis in KS−/− BAT was not accompanied by overt tissue remodeling even by 8 wk [Fig. 5E,F]. Therefore, WAT is highly sensitive to elevated PDGFRβ signaling, while BAT is resistant. Interestingly, WAT-selective remodeling was also reported in mice with elevated PDGFRα signaling [Sun et al. 2017]. In summary, PDGFRβ–STAT1 signaling causes atrophy of the dermis and WAT, but, in the absence of STAT1, PDGFRβD849V causes fibrolipoverative replacement of WAT with collagen-rich matrix [Fig. 5G].

VSMC hyperplasia in Pdgfrβ+/D849V aortas is STAT1-independent

PDGFRβD849V causes VSMC hyperplasia that leads to arterial stiffening and gradual outward remodeling of the aorta [Olson and Soriano 2011]. To determine whether STAT1 is required for PDGFRβD849V–induced VSMC hyperplasia, we generated a cohort of KS mutants with VSMC-selective Sm22a-Cre. This Cre driver is advantageous because mice survive up to 1 yr when PDGFRβD849V expression is restricted to VSMCs. At 6 wk of age, the KS+/- and KS−/− aortas were similarly dilated and dense with hyperplastic VSMCs compared with S+/+ and S−/− aortas [Supplemental Fig. S6A]. KS−/− aortas exhibited perivascular inflammation [Supplemental Fig. S6A, arrows], which was also shown previously in KS+/- aortas [He et al. 2015]. As expected, inflammation was rescued from KS−/− aortas but was replaced by fibrosis of the adventitia [Supplemental Fig. S6A, asterisks]. We also stained for the contractile VSMC markers α SMA, Sm22a, and SMMHC. These markers were down-regulated in KS−/− and KS+/- aortas compared with S+/+ and S−/− [Supplemental Fig. S6B], indicating a loss of contractile phenotype. These morphological and molecular changes show that PDGFRβD849V induces VSMC hyperplasia independently of STAT1.

Figure 4. PDGFRβ signaling causes dermal atrophy or dermal fibrosis. (A) Trichrome-stained dorsal skin from 3-wk-old mice. Arrows indicate dermal thickness [distance from the epidermal–dermal junction to the dermal–fat junction]. (B) Quantification of dermal thickness in tissue sections. Each data point represents the average of four measurements for one mouse. (***P < 0.001 KS+/− versus S+/−; ****P < 0.0001 KS−/− versus S−/−) by Student’s t-test. Data represent mean ± SD. (C–E) Immunofluorescence analysis of dWAT by staining for extracellular matrix (collagen 3), adipocyte cytoplasm (perilipin 1), or PDGFRβ with DAPI counterstain. Circled areas highlight clusters of interstitial cells. Bars: A, 100 µm; C–E, 20 µm.
STAT1 modulates PDGFRβ^D849V^-driven skeletal phenotypes

Skeletal phenotypes have not been shown in Pdgfrb^+/D849V^ mice but occur in humans with PDGFRB gain-of-function mutations. To address this discrepancy, we first analyzed skeletons by whole-mount staining at birth. At this time, we did not find consistent defects in KS^+/− or KS^-/- skeletons compared with S^+/− and S^-/-, but KS^+/− ribs were sometimes narrower (Supplemental Fig. S7). Instead, consistent differences were noted at 3 wk of age: By this time, S^+/− and S^-/- calvaria were mineralized and stained with Alizarin red, but KS^+/− calvaria were poorly mineralized and incompletely stained (Fig. 6A). Intriguingly, KS^-/- calvaria exhibited a granular staining pattern suggestive of internal changes (Fig. 6B). Upon sectioning the center of the calvaria, we found that the KS^-/- skulls had marrow-filled channels throughout the bone (Fig. 6C); similar channels were seen only near the sutures of 3-wk-old S^+/− and S^-/- calvaria [Supplemental Fig. S8]. In marked contrast to KS^-/- calvaria, KS^+/− calvaria were very thin and lacked marrow-filled channels (Fig. 6C,D). S^-/- calvaria were slightly thicker than S^+/− calvaria, consistent with previous reports [Xiao et al. 2004]. In all genotypes, PDGFRβ was expressed in the sagittal suture mesenchyme, where skeletal stem cells reside [Zhao et al. 2015], plus broad expression in the periosteum, dura, and endosteum, which are regions populated by more differentiated osteoblast lineage cells [Supplemental Fig. S8].

The ribcage was also altered in 3-wk-old PDGFRβ^D849V^- expressing mice. Each rib has a dorsal bony segment attached to the spine and a ventral cartilaginous segment attached to the sternum. A growth plate forms at the bone–cartilage interface in the middle of each rib. KS^-/- ribs were thin, and bone was poorly mineralized [Fig. 6E, Supplemental Fig. S9]. However, in KS^-/- ribs, the cartilage and bone near the growth plate were slightly enlarged, forming a noticeable bulge [Fig. 6E; Supplemental Fig. S9]. KS^-/- ribs also typically displayed ridges of nonmineralized tissue over the groove of Ranvier [Fig. 6E arrows]. This groove in the perichondrium forms at the periphery of the growth plate of most long bones and runs circumferentially around the bone. It is believed to harbor progenitor cells that govern circumferential growth of cartilage and the formation of periosteum around the growth plate [Shapiro et al. 1977; Karlsson et al. 2009; Yang et al. 2013]. Histological analysis of this region failed to show consistent differences between S^+/− and S^-/- bones, but the groove of KS^+/− ribs was typically shallow and hypocellular (Fig. 6F, boxed area enlarged below). In contrast, the groove of KS^-/- ribs was hyperplastic with an expansion of fibrous tissue superior to the groove (Fig. 6F), corresponding to the nonmineralized ridge of tissue noted by whole mount (Fig. 6E arrows). There was a slight but statistically significant increase in growth plate width in S^-/- ribs compared with S^+/− ribs, without a difference in height [Fig. 6G,H]. The KS^-/- growth plates were significantly enlarged. The KS^+/− growth plates appeared disorganized and lens shaped, with an average width intermediate between S^-/- and KS^-/- . Therefore, taking together the skull and rib defects, the pattern of bone phenotypes corresponds with the fat and skin phenotypes, where the KS^-/- tissues exhibit degenerative features, and the KS^+/− tissues exhibit overgrowth. Poor mineralization can result from inadequate levels of crucial metabolites, but we did not find significant differences in serum phosphate, calcium, or vitamin D among the four genotypes at 3 wk of age [data not shown].

In a cohort of S^+/− , S^-/- , and KS^-/- mice at 6–8 wk of age, ~75% of the KS^-/- mice were overgrown [defined as >25 g or at least two standard deviations above the average.
weight of controls] (Supplemental Fig. S10A,B). Since KS−/− mice are not obese, most of the increase in weight should be due to overgrowth of the skin, connective tissue, and skeleton. KS−/− mice also developed severe kyphosis and abnormally long ribs that caused the sternum to protrude [Supplemental Fig. S10A,C]. Moreover, after removing the skin, the KS−/− calvaria were red instead of the usual pale pink [Supplemental Fig. S11A]. Sectioning revealed that the color change was due to a greatly expanded marrow area [Supplemental Fig. S11B], which extended the observations in three wk-old KS−/− calvaria (Fig. 6C). Therefore, the suble skin and rib defects in 3-wk-old KS−/− mice presaged rapid skeletal overgrowth by 8 wk of age. In contrast, KS+/− mice exhibited underdeveloped or atrophied skull and rib bones, which was already quite severe by 3 wk. It is clear from these data that PDGFRβ regulates skeletal growth, a process that is strongly modified by the STAT1 pathway.

**Canonical IFN signaling is not required for PDGFRβD849V-driven wasting**

STAT1 is required for signaling by type I IFN [IFNα and IFNβ] and type II IFN [IFNγ]. These cytokines exert potent antiviral and anti-proliferative effects on most cell types by binding to receptor complexes that include Ifnar1 [IFNα and IFNβ receptor subunit 1] or Ifngr1 [IFNγ receptor subunit 1]. Excessive IFN signaling is detrimental. Mice and rats treated with IFN for the first week of life suffer lethal wasting [Gresser et al. 1980], which bears some similarity to KS−/− and KS+/− mice. A different cause is Trex−/− mice, which have constitutive activation of a cytosolic viral nucleic acid-sensing pathway that results in up-regulation of ISGs and lethal autoinflammation [Stetson et al. 2008]. Importantly, Trex−/− mice are rescued by deletion of Ifnar1, which proves that type I IFN signaling is central to pathology. Excessive IFN production is postulated to be directly involved in human genetic diseases called type 1 interferonopathies, in which autoinflammation is initially triggered by mutations in TREX or other cytosolic viral sensors [Crow et al. 2006; Crow and Manel 2015]. It is unclear whether PDGFRβD849V induces canonical IFN signaling or simply hijacks the pathway downstream through STAT1. We never detected increased IFN mRNA/protein in biological samples from PDGFRβD849V-expressing mice [Olson and Soriano 2011; He et al. 2015]. Nevertheless, even trace levels of IFN can induce cell responses. To directly evaluate the role of IFN receptor signaling in PDGFRβD849V-expressing mice, we generated cohorts with Sox2-Cre for activation of PDGFRβD849V and deletion of either Ifnar1 [designated A] or Ifngr1 [designated G]. Complete deletion of Ifnar1 improved the median survival of KA−/− pups by 4 d compared with KA−/− (P < 0.05), but wasting was still evident,
and no pups survived more than 3 wk [Fig. 7A,B]. Ifngr1 deletion had no effect on survival of KG−/− pups compared with KG+/− [Fig. 7C,D]. Since these genetic experiments failed to rescue autoinflammation-associated wasting, we conclude that IFNs themselves are not required. The small extension of life span in KA−/− mice suggests that Ifnar1 has a minor role in potentiating autoinflammation. Since tonic signaling through Ifnar1 is needed to maintain the basal expression of STAT1 [Gough et al. 2012], Ifnar1 deletion may improve survival of KA−/− mice by reducing initial levels of STAT1.

Discussion

How downstream pathways mediate the physiological and pathological effects of RTK signaling remains an open question. Here we addressed the function of the PDGFRβ–STAT1 pathway, finding that gain-of-function PDGFRβ signaling activates STAT1 and thereby induces autoinflammation and lethal wasting in young mice. It is noteworthy that KS−/− mice died in the third week postnatal because we reported previously that KS+/− mice died in the second week [Olson and Soriano 2011]. This difference is a good indication that juvenile lethality in Pdgfrb+/D849V mice is highly dependent on Stat1 gene dosage. However, wasting and early lethality still occurred in Pdgfrb+/D849V mice lacking IFN signaling (KA−/− and KG−/− mice), which shows that IFNs are not major drivers of these phenotypes. In addition, we showed that STAT1 suppresses PDGFRβD849V expression and signaling in dermal fibroblasts, PDGFRβ–STAT1 promotes lipoatrophy and wasting via autoinflammation, STAT1 inhibits PDGFRβD849V-driven fibrosis of skin and fat, and STAT1 modulates highly penetrant PDGFRβD849V-driven skeletal phenotypes. We can infer that PDGFRβ-regulated proteins besides STAT1 are the mediators of fibrosis and skeletal overgrowth in KS−/− mice. Our data point to PLCγ as a good candidate to mediate fibrosis and overgrowth because of enhanced phosphorylation in KS−/− compared with KS+/− cells. STAT3 and STAT5 are also interesting candidates because they were constitutively phosphorylated and their heterodimerization profiles could change without STAT1 [Delgoffe and Vignali 2013]. Future genetic studies will address their roles in PDGFRβD849V-driven phenotypes. Our finding that wasting or overgrowth phenotypes in KS−/− and KS+/− mice are differentially dependent on STAT1 highlights its role as a crucial mediator and modifier of PDGFRβ signaling.

Mutations in PDGFRB have been linked recently to Penttinen syndrome and Kosaki overgrowth syndrome, two rare genetic conditions that affect the skin, fat, and bones in distinct ways [Johnston et al. 2015; Takenouchi et al. 2015]. Two mutations, V665A and P584R, have been characterized biochemically as gain-of-function mutations [Johnston et al. 2015; Arts et al. 2016], but functional evidence that elevated PDGFRβ signaling causes overgrowth or wasting of connective tissue was lacking. Our studies in Pdgfrb+/D849V mice reveal significant phenotypic overlap with humans. This is strong functional evidence that PDGFRB mutations are causal. This conclusion is further supported by the report of a patient with an N666H gain-of-function mutation in PDGFRB and overlapping phenotypes with Penttinen syndrome and Kosaki overgrowth syndrome who developed clinical improvement when treated with imatinib, an inhibitor of several kinases, including PDGFRB [Pond et al. 2017]. Table 1 summarizes the phenotypic spectrum of KS+/− and KS−/− mice and correspondence to phenotypes described in human PDGFRB-related syndromes. In the skeleton, KS−/− mice exhibit thin bones reminiscent of Penttinen syndrome, while KS+/− mice develop overgrowth during adolescence that aligns very well with Kosaki overgrowth syndrome. In the skin and fat, KS−/− mice exhibit dermal wasting and lipoatrophy. Penttinen syndrome patients are described as having thin or translucent skin with prominent venous patterning plus lipoatrophy and a prematurely aged appearance. We show that KS−/− mice develop...
dermal fibrosis and fat remodeling that is distinct from lipoatrophy in KS\(^{+/−}\) mice. Similarly, Kosaki overgrowth syndrome is characterized by dermal and fat remodeling that appears phenotypically distinct from Penttinen syndrome.

There are some nonoverlapping phenotypes between \textit{Pdgfrb}\(^{D849V}\) mutant mice and humans with \textit{PDGFRB}-associated syndromes, which highlights areas for future investigation (Table 1). Autoinflammation has not been characterized in humans. However, constitutive phosphorylation of STAT1 by the V664A and P583R mutant was not rescued by PDGFRB\(^{D842V}\) mutation caused multiorgan fibrosis, but PDGFRB\(^{D849V}\) caused autoinflammation without fibrosis [Olson and Soriano 2009, 2011; Iwayama and Olson 2013; Iwayama et al. 2015]. A comparison in skeletal muscle also found greater fibrogenic potential from PDGFRB [Ieronimakis et al. 2016]. A reason for this functional difference is revealed by our genetic studies: The profibrotic effects of PDGFRB\(^{D849V}\) are limited by STAT1 activity. This is not the case for PDGFRB\(^{D842V}\), which induces weak STAT1 phosphorylation compared with PDGFRB\(^{D849V}\) in transient transfection experiments [data not shown].

PDGFR\(β\) is crucial for the development of the craniofacial bones and axial skeleton [Klinghoffer et al. 2002; Moenning et al. 2009; Olson and Soriano 2009; He and Soriano 2013; Fantauzzo and Soriano 2014]. More recent work has shown that PDGFR\(β\) has a role in neural crest-directed development of craniofacial bones, where it cooperates with PDGFR\(α\) [Fantauzzo and Soriano 2016]. However, a role for either receptor in the postnatal skeleton has been less clear. Our results show that elevated PDGFR\(β\) signaling causes skeletal defects that are reminiscent of human disease. These phenotypes may arise from defective behavior of bone stem/progenitor cells, but this requires further investigation. It is known that osteoclasts, a hematopoietic cell type involved in bone reabsorption, secrete PDGF-B to recruit PDGFR\(β\) osteoblast precursors to sites of bone formation [Kubota et al. 2002; Sanchez-Fernandez et al. 2008]. PDGF can increase bone strength in rodents either when administered systematically or by implantation of hematopoietic cells engineered to secrete PDGF-B [Mitlak et al. 1996; Chen et al. 2015]. However, it is unclear which receptor mediates this effect because PDGF-B can activate both PDGFR\(α\) and PDGFR\(β\).

In cultured bone marrow stromal cells, PDGFR\(β\) supports proliferation and migration while inhibiting osteogenic differentiation [Tokunaga et al. 2008]. Elevated PDGFR\(β\)

### Table 1. Phenotypes in KS\(^{+/−}\) and KS\(^{−/−}\) mutant mice compared with reports of humans with gain-of-function PDGFRB mutations

| Mouse phenotypes | Mouse genotype | Role of STAT1 | Human phenotypes | Human genotype\(^a\) | References |
|------------------|----------------|--------------|------------------|---------------------|-----------|
| KS degeneration  | \(KS^{+/−}\)  | Promotes     | Thin calvaria and bones, acroosteolysis, osteopenia | V665A | Johnston et al. 2015 |
| KS overlapping   | \(KS^{−/−}\)  | Inhibits     | Skeletal overgrowth, thick calvaria with diffuse granular pattern | P584R, W566R | Takenouchi et al. 2015; Minatogawa et al. 2017 |
| Lipoatrophy      | \(KS^{+/−}\)  | Promotes     | Lipatrophy, thin/translucent skin, prematurely aged appearance | V665A | Johnston et al. 2015 |
| Fibrosis of skin/fat | \(KS^{−/−}\)  | Inhibits     | Lipodystrophy, hyperelastic skin | P584R, W566R | Takenouchi et al. 2015; Minatogawa et al. 2017 |
| Vascular defects | \(KS^{+/−}\)  | Promotes     | Not characterized | P584R, W566R | Takenouchi et al. 2015; Minatogawa et al. 2017 |
| Not characterized | \(KS^{+/−}\), \(KS^{+/−}\) | Independent\(^b\) | Intellectual disability, white matter lesions | P584R, W566R | Takenouchi et al. 2015; Minatogawa et al. 2017 |

\(^a\)The V665A mutation is linked to Penttinen syndrome. The P584R and W566R mutations are linked to Kosaki overgrowth syndrome.

\(^b\)Vascular defects involving VSMC hyperplasia and aortic dilation are STAT1-independent. However, perivascular autoinflammation is STAT1-dependent (He et al. 2015).
signaling would thus be expected to enhance osteoprogenitor proliferation and migration. We now show that PDGFRβ indeed regulates postnatal bone growth. Paradoxically, PDGFRβ<sup>D849V</sup> either inhibits or enhances bone growth in the presence or absence of STAT1, respectively. However, one caveat for understanding PDGFRβ–STAT1 signaling in bones is that Stat1<sup>−/−</sup> mice have mildly increased bone growth, as we confirmed in S<sup>−/−</sup> calvaria (thickness) and growth plates [width]. Increased osteoblast/chondroblast proliferation in S<sup>−/−</sup> mice has been explained by changes in Runx2 transcriptional activity and expression in Runx2 transcriptional activity and Fgfr3 signaling (Kim et al. 2003; Murakami et al. 2004; Xiao et al. 2004), but PDGFRβ was not examined. Therefore, as STAT1 likely touches multiple aspects of bone growth and remodeling, the Stat1<sup>−/−</sup> background may amplify the effect of PDGFRβ<sup>D849V</sup> in bones through more than one mechanism.

Materials and methods

Mice

Mouse strains PDGFRβ<sup>D849V</sup> [018435], Sox2-Cre [008454], Sm22a-Cre [017491], STAT1<sup>lox/lox</sup> [012901], Ifnar1<sup>lox/lox</sup> [028256], and Irng<sup>lox/lox</sup> [025394] are available at the Jackson Laboratory. The Institutional Animal Care and Use Committee of the Oklahoma Medical Research Foundation approved all procedures performed on mice. Mice were examined in a mixed C57BL/6/129Sv genetic background and were fed a standard mouse chow diet. Littermates were used whenever possible.

PDGFRβ expression in NIH3T3 cells

Vectors were created to express wild-type mouse PDGFRβ or mutant isoforms with single amino acid change P583R, V664A, or D850V (corresponding to human P584R, V665A, or D850V). First, PCR-amplified wild-type or mutant cDNAs were inserted in pENTR [a gateway cloning-compatible construct; gift from Eric Campeau]. Each construct was then mixed with pLenti CMV D849V (corresponding to human P584R, V665A, or D850V). First, PCR-amplified wild-type or mutant cDNAs were inserted in pENTR [a gateway cloning-compatible construct; gift from Eric Campeau]. Each construct was then mixed with pLenti CMV D849V (corresponding to human P584R, V665A, or D850V). First, PCR-amplified wild-type or mutant cDNAs were inserted in pENTR [a gateway cloning-compatible construct; gift from Eric Campeau]. Each construct was then mixed with pLenti CMV D849V (corresponding to human P584R, V665A, or D850V). First, PCR-amplified wild-type or mutant cDNAs were inserted in pENTR [a gateway cloning-compatible construct; gift from Eric Campeau]. Each construct was then mixed with pLenti CMV D849V (corresponding to human P584R, V665A, or D850V).

RNA isolation and quantitative RT–PCR (qRT–PCR)

Total RNA was isolated from mouse ingWAT tissues using RNeasy kit [Qiagen] or from cultured DFs using Trizol (ThermoFisher). cDNA reverse transcription was performed using random primers and SuperScript III RT [Invitrogen]. qPCR was performed on a Bio-Rad iCycler with iQ SYBR Green master mix. Results were normalized to Gapdh. Primer sequences are listed in the Supplemental Material.

Flow cytometry

Fat pads [ingWAT] were minced and digested with 300 μg/mL collagenase type I [Life Technologies] in Hank's balanced salt solution [pH 7.4] for 60 min at 37 °C. After filtering (70-μm filter), cells were resuspended in PBS with 1 mM EDTA and 2% FBS and incubated with Fc-blocking antibody [Bioscience] for 15 min on ice before staining with FITC-CD45.2 antibody [1:100, Biolegend]. Cells were also stained with propidium iodide to identify live/dead cells. After washing, immunofluorescence was detected by an LSR II [BD Biosciences]. Data were analyzed by post-collection compensation using Flowjo software [Tree Star, Inc.].

Primary DFs and Western blotting

After removing hair with cream [Nair], mouse DFs were isolated from 2- to 3-wk-old mice by explanting 1-mm² pieces of skin, dermis side down, with DMEM plus 10% FBS, 25 U/mL penicillin/streptomycin, and 2 mM L-glutamine. After 2 wk, skin pieces were removed, and DFs were passaged. All assays were performed at passages 2–5. For Western blotting, cells were starved in medium containing 0.1% FBS for 24 h and then treated with 10 ng/mL PDGF-BB [R&D Systems] for 10 min or according to a time course. Cells were lysed in RIPA buffer [50 mM Tris at pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 0.1% sodium dodecyl sulfate] with 1 mM NaF, Na<sub>3</sub>VO₄, PMSE, and 1× protease inhibitor cocktail [Complete, Roche], and protein concentration was determined by Pierce BCA assay [ThermoFisher]. Five micrograms or 10 μg of protein was then separated by SDS-PAGE and transferred to nitrocellulose membranes, blocked with 5% BSA, and then subjected to Western blotting with primary antibodies listed in the Supplemental Material. Membranes were then probed with horseradish peroxidase-conjugated secondary antibodies at 1:5000 [Jackson ImmunoResearch] in 5% milk. Blots were developed with Pierce ECL Western blotting substrate [ThermoFisher] and autoradiography film [Santa Cruz Biotechnology].

Tissue and histology

Tissue was immersion-fixed overnight in 4% paraformaldehyde [PFA; Electron Microscopy Sciences] or Bouin’s fixative [Sigma]. Hair was removed with cream [Nair]. Bones were decalcified in 10% EDTA solution for 1 wk. For histochemical staining, Bouin’s-fixed tissues were embedded in paraffin and sectioned at 5 μm before staining with Masson’s Trichrome [Electron Microscopy Sciences] or hematoxylin and eosin [Vector Laboratories]. For immunohistochemistry, PFA-fixed samples were cryosectioned at 8 μm and stained with primary antibodies listed in the Supplemental Material. This was followed by the appropriate donkey secondary antibodies [Jackson ImmunoResearch] and DAPI [Sigma] as a nuclear stain. Immunofluorescence microscopy was performed with a Nikon Eclipse 80i microscope connected to a digital camera.

Whole-mount analysis of bones

Skin was removed, and pups were fixed in 100% EtOH for 3 d followed by Alcian blue stain [15 mg of Alcian blue, 80 mL of 95% EtOH, 20 mL of glacial acetic acid] for 12 h. Next, the skeletons were rinsed in 100% EtOH overnight, cleared in 1% KOH for 6 h, and then counterstained in 5 mg of Alizarin red in 100 mL of 1% KOH overnight. Skeletons were then cleared in 1% KOH, washed in a graded series of 1% KOH and glycerol, and finally allowed by Alcian blue stain (15 mg of Alcian blue, 80 mL of 95% EtOH, 20 mL of glacial acetic acid) for 12 h. Next, the skeletons were rinsed in 100% EtOH overnight, cleared in 1% KOH for 6 h, and then counterstained in 5 mg of Alizarin red in 100 mL of 1% KOH overnight. Skeletons were then cleared in 1% KOH, washed in a graded series of 1% KOH and glycerol, and finally stored in 100% glycerol. Adult skeletons were treated similarly except for overnight trypsin treatment [1% trypsin in 7:3 distilled H<sub>2</sub>O:saturated sodium borate solution] before preclearing in 2% KOH, and all subsequent steps were performed in 2% KOH.
Data are expressed as mean ± standard deviation unless indicated otherwise. All calculations were performed using GraphPad Prism 6.0. The differences between two groups (usually S+/− vs. KS+/−, or S−/+ vs. KS−/+′) were assessed by unpaired Student’s t-test unless indicated otherwise. A value of P < 0.05 was considered statistically significant. The significant differences in mouse survival were determined by a log-rank test.

Acknowledgments

We thank Cameron Steele, Tony Tang, Linda Thompson, James Tomasek, Mary Beth Humphrey, and Yanick Crow for their assistance and helpful discussion. We also thank the Flow Cytometry Core Facility and Imaging Core Facility [associated with P20GM103636] and the Mouse Phenotyping Core Facility [associated with P30GM114731] of the Oklahoma Medical Research Foundation Centers of Biomedical Research Excellence. These studies were funded by National Institutes of Health grants (P20GM103636 and R01AR070235), a grant from the Oklahoma Center for Adult Stem Cell Research, and the Pew Charitable Trusts. C.S. and S.C.M. were supported by predoctoral fellowships from the American Heart Association.

References

Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276–1312.

Arts FA, Chand D, Peccquet C, Velghe AI, Constantinescu S, Hällberg B, Demoulin JB. 2016. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene 35: 3239–3248.

Bonner JC. 2004. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255–273.

Chen W, Raylink DJ, Brier-Jones J, Neises A, Kiroyan JB, Rundle KS, Lau KH, Zhang XB. 2015. PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proc Natl Acad Sci 112: E3893–E3900.

Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen VH, Guo J, Qi M, Guan Y, Albrecht S, et al. 2013. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet 92: 996–1000.

Crow YJ, Manel N. 2015. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol 15: 429–440.

Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, Black DN, van Bokhoven H, Brunner HG, Hambel BC, et al. 2006. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 38: 917–920.

Delgoffe GM, Vignali DA. 2013. STAT heterodimers in immunity: a mixed message or a unique signal? JAKSTAT2: e23060.

Driskell RR, Jahoda CA, Chuong CM, Watt FM, Horsley V. 2014. Defining dermal adipose tissue. Exp Dermatol 23: 629–631.

Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443–450.

Fantauzzo KA, Soriano P. 2014. PI3K-mediated PDGFRα signaling regulates survival and proliferation in skeletal development through p38-dependent intracellular pathways. Genes Dev 28: 1005–1017.

Fantauzzo KA, Soriano P. 2016. PDGFRα regulates craniofacial development through homodimers and functional heterodimers with PDGFRβ. Genes Dev 30: 2443–2458.

Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36: 166–174.

Gresser I, Morel-Maroger L, Riviere Y, Guillon JC, Tovey MG, Woodrow D, Sloper JC, Moss J. 1980. Interferon-induced disease in mice and rats. Ann NY Acad Sci 350: 12–20.

He F, Soriano P. 2013. A critical role for PDGFRα signaling in medial nasal process development. PLoS Genet 9: e1003851.

He C, Medley SC, Hu T, Hinsdale ME, Lupo F, Virmani R, Olson LE. 2015. PDGFRβ signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis. Nat Commun 6: 7770.

Heldin CH, Westmark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283–1316.

Ieronimakis N, Hays A, Prasad A, Janehodin K, Duffield JS, Reyes M. 2016. PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. J Pathol 240: 410–424.

Iwayama T, Olson LE. 2013. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Curr Rheumatol Rep 15: 304.

Iwayama T, Steele C, Yao L, Dozomorov MG, Karamichos D, Wren JD, Olson LE. 2015. PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. Genes Dev 29: 1106–1119.

Johnston JJ, Sanchez-Contreras MY, Kepller-Noreuil KM, Sapp J, Crenshaw M, Finch NA, Cormier-Daire V, Rademakers R, Sybert VP, Biesecker LG. 2015. A point mutation in PDGFRB causes autosomal-dominant Penttinne syndrome. Am J Hum Genet 97: 465–474.

Karlsson C, Thornemo M, Henriksson HB, Lindahl A. 2009. Identification of a stem cell niche in the zone of Ranvier within the knee joint. J Anat 215: 355–363.

Kazi IU, Kabir NN, Flores-Morales A, Ronnstrand L. 2014. SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci 71: 3297–3310.

Keller A, Westenberger A, Sobrido MJ, Garcia-Murias M, Domingo A, Sears RL, Lemos RR, Ordonez-Ugalde A, Nicolas G, da Cunha JE, et al. 2013. Mutations in the gene encoding PDGFB cause brain calcifications in humans and mice. Nat Genet 45: 1077–1082.

Kim S, Koga T, Isebo M, Kern BE, Yokochi T, Chin YE, Karsenty G, Taniguchi T, Takayanagi H. 2003. Stat1 functions as a cyttoplasmic attenuator of RUNX2 in the transcriptional program of osteoblast differentiation. Genes Dev 17: 1979–1991.

Klinghoffer RA, Hamilton TG, Hoch R, Soriano P. 2002. An allelic series at the PDGFRα locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell 2: 103–113.

Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakahayashi K. 2002. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 17: 257–265.

Levy DE, Darnell JE Jr. 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.

Linossi EM, Babin JJ, Hilton DJ, Nicholson SE. 2013. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev 24: 241–248.

Makino K, Makino T, Stawski L, Mantero JC, Lafaytis R, Simms R, Trojanowska M. 2017. Blockade of PDGFR receptor by crenolanib has therapeutic effect in patient fibroblasts and in
preclinical models of systemic sclerosis. *J Invest Dermatol* **137**:1671–1681.

Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, Guo Y, Zand DJ, Bernstein AM, Masur SK, et al. 2013. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. *Am J Hum Genet* **92**:1001–1007.

Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway. *Cell* **84**:431–442.

Minatogawa M, Takenouchi T, Tsuyusaki Y, Iwasaki F, Uehara T, Mitlak BH, Finkelman RD, Hill EL, Li J, Martin B, Smith T, DMoenning A, Jager R, Egert A, Kress W, Wardelmann E, Schorle H, Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crom-Nicolas G, Pottier C, Maltete D, Coutant S, Rovelet-Lecrux A, Olson LE, Soriano P. 2011. PDGFRβ signaling regulates mural cell development and drives systemic fibrosis. *J Bone Joint Surg Am* **59**:703–723.

Silvennoinen O, Schindler C, Schlessinger J, Levy DE. 1993. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. *Science* **261**:1786–1789.

Stetson DB, Ko JS, Heidmann T, Medzhitov R. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. *Cell* **134**:587–598.

Sahni M, Raz R, Coffin JD, Levy D, Basilico C. 2001. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. *Development* **128**:2119–2129.

Sanchez-Fernandez MA, Gallois A, Reidl T, Jurdic P, Hoflack B. 2008. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PGDF receptor β signaling. *PLoS One* **3**:e3537.

Shapiro F, Holtrop ME, Glimerch MJ. 1977. Organization and cellular biology of the perichondrial ossification groove of ranvier: a morphological study in rabbits. *J Bone Joint Surg Am* **59**:703–723.